Study finds increased risk of stroke following shingles, suggests antiviral treatment may
Patients' risk of stroke significantly increased following the first signs of shingles, but antiviral drugs appeared to offer some protection, according to a new study in Clinical Infectious Diseases, now available online.
People with shingles, an often painful skin rash caused by the same virus that causes chickenpox, had a higher stroke risk in the first 6 months after shingles symptoms appeared; this risk was particularly increased in patients with a rash near their eyes, the study found.
Shingles, or herpes zoster, is a significant public health problem, affecting an estimated 1 million adults in the U.S. and nearly 90,000 in the U.K. each year. The disease develops when the varicella-zoster virus, which causes chickenpox in children and then remains dormant in the body, reactivates later in life.
Sinéad Langan, MD, PhD, and colleagues at the London School of Hygiene & Tropical Medicine identified patients with first-ever incidents of shingles and stroke, and also examined antiviral treatment records for shingles, drawing from a database of information from patients across 600 general practices in the U.K.
Researchers compared the risk of stroke in the time period after the patient had shingles to time periods when the patient did not have recent shingles. Among the 6,584 patients included in the study, the stroke rate was 63 percent higher in the first four weeks after a shingles episode compared to the patient's baseline risk, diminishing slowly up to 6 months later. The stroke risk increased up to three-fold for a short period of time among those with a shingles rash affecting the skin around their eyes, compared to baseline risk.
In patients treated with oral antiviral medication for their shingles—55 percent of study participants—the risk of stroke was lower than in those not treated with antivirals. "The relatively low prescribing rates of antiviral therapy in U.K. general practice after developing shingles need to be improved," Dr. Langan said, "as our study suggests that stroke risks following shingles are lower in those treated with oral antiviral therapy compared to individuals not treated with antiviral therapy."
The findings also highlight the importance of vaccinating older adults against shingles, which can reduce the risk of developing the painful condition in the first place. A shingles vaccine is available and recommended for adults over 60 in the U.S. and for those in their 70s in the U.K.
In a related editorial, Maria A. Nagel, MD, and Donald H. Gilden, MD, of the University of Colorado School of Medicine, noted that the findings confirm previous studies of shingles and stroke risk from Taiwan, Denmark, and the U.K. This latest study is "the first to show that the increased risk of stroke after zoster can be reduced with antiviral treatment," they wrote.
Editor's note: The research was funded by the U.K.'s National Institute for Health Research (NIHR) and the Stroke Association. The views expressed are those of the author(s) and not necessarily those of the funders, the U.K. National Health Service (NHS), or the U.K. Department of Health.
1. An often painful skin rash, shingles (herpes zoster) affects an estimated 1 million adults in the U.S. and nearly 90,000 in the U.K. each year.
2. People with shingles, particularly those with a rash near their eyes, had a higher stroke risk in the first 6 months after their symptoms appeared, this study found.
3. Antiviral treatment for shingles appeared to lower this increased risk of stroke.
Clinical Infectious Diseases is a leading journal in the field of infectious disease with a broad international readership. The journal publishes articles on a variety of subjects of interest to practitioners and researchers. Topics range from clinical descriptions of infections, public health, microbiology, and immunology to the prevention of infection, the evaluation of current and novel treatments, and the promotion of optimal practices for diagnosis and treatment. The journal publishes original research, editorial commentaries, review articles, and practice guidelines and is among the most highly cited journals in the field of infectious diseases. Clinical Infectious Diseases is an official publication of the Infectious Diseases Society of America (IDSA). Based in Arlington, Va., IDSA is a professional society representing nearly 10,000 physicians and scientists who specialize in infectious diseases. For more information, visit http://www.idsociety.org. Follow IDSA on Facebook and Twitter.
Matt Sobczak | idw - Informationsdienst Wissenschaft
Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT
Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
07.12.2016 | Earth Sciences
07.12.2016 | Earth Sciences
07.12.2016 | Materials Sciences